Literature DB >> 9085148

Immunohistochemical localization of muscarinic acetylcholine receptors in primary and metastatic malignant melanomas.

M Lammerding-Köppel1, S Noda, A Blum, G Schaumburg-Lever, G Rassner, U Drews.   

Abstract

In embryos morphogenetically active cells transiently express the cholinergic system comprising cholinesterase activity and muscarinic acetylcholine receptors. Malignant melanomas develop from melanocytes, which are derived from the neural crest. Neural crest cells express the embryonic muscarinic system during migration. Using the monoclonal antibody M35, we now show that normal melanocytes carry no muscarinic receptors, whereas malignant melanoma cells express them again. In primary melanomas and metastatic melanomas, we identified muscarinic receptors in solid strands or groups of atypical cells. In all primary malignant melanomas studied we found inhomogeneous distributions of M35-immunoreactivity subdividing the tumors into three different zones. In the tumor center, groups or single cells often showed only little or even no immunofluorescence. In contrast, pericentrally we detected strong immunostaining in the conglomerations of atypical melanocytes. In the peripheral infiltration zone, intensely fluorescent cells in clusters or single, were spreading into the normal tissue, leading to a more patchy staining pattern. Melanocytes of nevi also possess muscarinic receptors, showing similar distribution patterns as in the melanoma. We suggest that in malignant melanomas muscarinic receptors might play a regulative role in infiltrative growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085148     DOI: 10.1111/j.1600-0560.1997.tb01567.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  9 in total

1.  Identification and characterization of muscarinic acetylcholine receptor subtypes expressed in human skin melanocytes.

Authors:  R Buchli; A Ndoye; J Arredondo; R J Webber; S A Grando
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

2.  Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression.

Authors:  J A Reed; B Finnerty; A P Albino
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.

Authors:  D Fang; J Hallman; N Sangha; T E Kute; J A Hammarback; W L White; V Setaluri
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 4.  Muscarinic receptor agonists and antagonists: effects on cancer.

Authors:  Eliot R Spindel
Journal:  Handb Exp Pharmacol       Date:  2012

5.  Suitability of Nicotinic Acetylcholine Receptor α7 and Muscarinic Acetylcholine Receptor 3 Antibodies for Immune Detection: Evaluation in Murine Skin.

Authors:  Frank R Rommel; Badrinarayanan Raghavan; Renate Paddenberg; Wolfgang Kummer; Susanne Tumala; Günter Lochnit; Uwe Gieler; Eva M J Peters
Journal:  J Histochem Cytochem       Date:  2015-02-11       Impact factor: 2.479

6.  Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.

Authors:  Nityanand Maddodi; Kumar M R Bhat; Sulochana Devi; Su-Chun Zhang; Vijayasaradhi Setaluri
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

7.  Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma.

Authors:  Y H Liao; S M Hsu; H L Yang; M S Tsai; P H Huang
Journal:  Br J Cancer       Date:  2011-02-22       Impact factor: 7.640

8.  Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Authors:  Oxana Dobrovinskaya; Georgina Valencia-Cruz; Luis Castro-Sánchez; Edgar O Bonales-Alatorre; Liliana Liñan-Rico; Igor Pottosin
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

9.  M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells.

Authors:  Luca Pacini; Elena De Falco; Maria Di Bari; Andrea Coccia; Camilla Siciliano; Donatella Ponti; Antonio Luigi Pastore; Vincenzo Petrozza; Antonio Carbone; Ada Maria Tata; Antonella Calogero
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.